A recent systematic review and meta-analysis published in @TheLancet found that roughly 60% of bacterial co-infections or secondary infections in #COVID19 patients were resistant to antimicrobials.
Over 200 studies published in peer-reviewed journals have featured T2MR in a breadth of applications.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
© 2022 T2 Biosystems, Inc.
A recent systematic review and meta-analysis published in @TheLancet found that roughly 60% of bacterial co-infections or secondary infections in #COVID19 patients were resistant to antimicrobials.
Sepsis has been included in the federal budget, thanks to the advocacy of organizations like @EndSepsis. The budget directs funding for comprehensively studying the burden of sepsis in the US healthcare system and a review of sepsis quality measures.
Please tell us where you are visiting from: United States | Outside the United States